The candidate malaria vaccine RTS,S/AS01E has entered phase 3 trials, but data on long-term outcomes are limited. Over a period of 4 years, 118 of 223 children who received the RTS,S/AS01E vaccine and ...
An ongoing phase 3 study of the efficacy, safety, and immunogenicity of candidate malaria vaccine RTS,S/AS01 is being conducted in seven African countries. In the 14 months after the first dose of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback